An international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies – and thus vulnerabilities – of pancreatic cancer stem cells.
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
In a study of people with nonalcoholic fatty liver disease and their twins and other close relatives, UC San Diego researchers were able to diagnose liver cirrhosis simply by analyzing a person’s stool microbes.
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, report on a novel four-year, randomized clinical trial evaluating different home-based methods to assess cognitive function and decline in participants over the age of 75.
Developing how the heart forms and brain works. How to analyze sarcasm computationally. Harnessing computers to develop campaign rhetoric across the spectrum. Halıcıoğlu Data Science Institute announced innovative undergraduate research scholarship projects across academic disciplines.
UC San Diego School of Medicine research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.
U.S. News & World Report, June 16
U.S. News & World Report, June 9
Women's Health, June 3
The New York Times, June 2
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
